Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Ardsley Advisory Partners LP

Ardsley Advisory Partners LP trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 15.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 300,000 shares of the company's stock after selling 52,900 shares during the period. Ardsley Advisory Partners LP's holdings in Teva Pharmaceutical Industries were worth $6,612,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TEVA. Diversify Advisory Services LLC increased its position in shares of Teva Pharmaceutical Industries by 2.5% during the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after purchasing an additional 496 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Teva Pharmaceutical Industries by 0.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after buying an additional 699 shares in the last quarter. Townsquare Capital LLC lifted its stake in shares of Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after buying an additional 812 shares in the last quarter. Metis Global Partners LLC boosted its position in Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock worth $302,000 after acquiring an additional 860 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its stake in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after acquiring an additional 949 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.22 on Friday. The stock has a market capitalization of $18.39 billion, a P/E ratio of -11.19, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a 50 day moving average price of $15.11 and a 200 day moving average price of $17.49.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on TEVA shares. Barclays dropped their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. UBS Group lowered their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Bank of America cut their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of "Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.